Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! View ALL results for your Stocks, ETFs and Funds Screeners with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Biontech Se ADR (BNTX)

Biontech Se ADR (BNTX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 22,301,258
  • Shares Outstanding, K 240,393
  • Annual Sales, $ 2,977 M
  • Annual Income, $ -719,920 K
  • EBIT $ -1,434 M
  • EBITDA $ -1,112 M
  • 60-Month Beta 1.35
  • Price/Sales 7.46
  • Price/Cash Flow N/A
  • Price/Book 1.11

Options Overview Details

View History
  • Implied Volatility 49.86% ( +1.94%)
  • Historical Volatility 75.27%
  • IV Percentile 82%
  • IV Rank 52.73%
  • IV High 70.47% on 04/08/25
  • IV Low 26.87% on 05/20/24
  • Put/Call Vol Ratio 1.27
  • Today's Volume 3,264
  • Volume Avg (30-Day) 2,347
  • Put/Call OI Ratio 0.73
  • Today's Open Interest 49,459
  • Open Int (30-Day) 53,029

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 18 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/25
See More
  • Average Estimate -2.96
  • Number of Estimates 9
  • High Estimate -2.22
  • Low Estimate -3.48
  • Prior Year -3.62
  • Growth Rate Est. (year over year) +18.23%

Price Performance

See More
Period Period Low Period High Performance
1-Month
89.77 +8.43%
on 05/15/25
120.62 -19.30%
on 04/24/25
-1.42 (-1.44%)
since 04/17/25
3-Month
81.20 +19.88%
on 04/07/25
123.87 -21.42%
on 02/21/25
-22.24 (-18.60%)
since 02/19/25
52-Week
76.53 +27.19%
on 08/05/24
131.49 -25.97%
on 09/17/24
+6.73 (+7.43%)
since 05/17/24

Most Recent Stories

More News
Why BioNTech Stock Got Trounced on Tuesday

An unhealthy combination of factors resulted in an unhealthy day on the stock market for next-generation healthcare company BioNTech (NASDAQ: BNTX) . Investors were concerned about the latest top-level...

NFLX : 1,184.20 (-0.62%)
C : 76.12 (+0.53%)
PFE : 22.94 (+0.48%)
BNTX : 97.52 (+5.12%)
Want Safe Dividend Income in 2025 and Beyond? Invest in the Following 3 Ultra-High-Yield Stocks.

There's no need to track down complicated and obscure businesses. Some of the market's best income-producing stocks are hiding in plain sight.

DG : 98.36 (+5.14%)
BTI : 43.29 (+1.52%)
WYNN : 96.64 (-0.12%)
FDX : 226.06 (-1.50%)
PFE : 22.94 (+0.48%)
O : 56.21 (-0.05%)
WMT : 98.06 (-0.18%)
BNTX : 97.52 (+5.12%)
Pfizer Q1 Earnings Beat Estimates, Several Headwinds Hurt Sales

Pfizer PFE reported first-quarter 2025 adjusted earnings per share of 92 cents, which comprehensively beat the Zacks Consensus Estimate of 64 cents per share. Earnings rose 12% year over year.Revenues...

JNJ : 152.23 (+0.59%)
PFE : 22.94 (+0.48%)
BMY : 46.87 (+0.26%)
BNTX : 97.52 (+5.12%)
Why Biotech Stars Summit Therapeutics and BioNTech Plunged, Even as This Chinese Rival Surged Today

Shares of biotech companies involved in the development of monoclonal antibody cancer therapies were moving all over the place on Friday. Both U.S.-based Summit Therapeutics (NASDAQ: SMMT) and BioNTech...

SMMT : 23.31 (-2.35%)
AKESF : 10.7665 (+1.57%)
BNTX : 97.52 (+5.12%)
Novavax Retail Traders Rally In Defense After RFK Jr.'s COVID-19 Vaccine Skepticism Sends Stock Tumbling

Kennedy singled out the Novavax COVID-19 shot's single-antigen composition as the reason behind the delay in granting full approval.

NVAX : 7.95 (+18.13%)
MRNA : 26.35 (+5.99%)
PFE : 22.94 (+0.48%)
BNTX : 97.52 (+5.12%)
Pfizer Stock Falls to New 52-Week Low: Should You Buy the Dip?

Pfizer’s PFE stock hit a new 52-week low of $20.92 on Wednesday but recovered thereafter and closed at $22.49Though the stock has seen ups and downs in the past year, the latest price decline is largely...

LLY : 753.20 (-0.55%)
ABBV : 185.16 (+0.62%)
PFE : 22.94 (+0.48%)
BNTX : 97.52 (+5.12%)
Moderna Stock: Is MRNA Underperforming the Healthcare Sector?

As Moderna has underperformed its broader sector recently, analysts remain cautious about the stock’s prospects.

XLV : 133.91 (+0.62%)
NVAX : 7.95 (+18.13%)
MRNA : 26.35 (+5.99%)
PFE : 22.94 (+0.48%)
BNTX : 97.52 (+5.12%)
BioNTech's 2025 Revenue View, Vaccine Policy Uncertainty Prompt Price-Target Cut: Retail Stays Cautiously Optimistic

For the current year, BioNTech projected revenue of 1.7 billion euros to 2.2 billion euros, below the market consensus of 2.54 billion euros and a fall from last year's 2.75 billion euros.

IBB : 121.72 (+0.46%)
FNDF : 38.46 (+0.47%)
PFE : 22.94 (+0.48%)
BNTX : 97.52 (+5.12%)
BioNTech Se (BNTX) Q4 2024 Earnings Call Transcript

BNTX earnings call for the period ending December 31, 2024.

BNTX : 97.52 (+5.12%)
BioNTech Surpasses Q4 Revenue Estimates

BioNTech SE exceeded earnings expectations with strong oncology pipeline development, despite reduced vaccine revenue.

MRNA : 26.35 (+5.99%)
PFE : 22.94 (+0.48%)
BNTX : 97.52 (+5.12%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 64% Sell with a Weakening short term outlook on maintaining the current direction.

See More Share

Business Summary

BioNTech SE is a biotechnology company. It develops and commercializes immunotherapies for cancer and other diseases. BioNTech SE is based in Mainz, Germany.

See More

Key Turning Points

3rd Resistance Point 94.74
2nd Resistance Point 93.95
1st Resistance Point 93.36
Last Price 97.52
1st Support Level 91.99
2nd Support Level 91.20
3rd Support Level 90.61

See More

52-Week High 131.49
Fibonacci 61.8% 110.50
Fibonacci 50% 104.01
Fibonacci 38.2% 97.52
Last Price 97.52
52-Week Low 76.53

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar